Cargando…

MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor

BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuya, Koichi, Deguchi, Shoichi, Muto, Manabu, Yasui, Kazuaki, Onoe, Tsuyoshi, Ogawa, Hirofumi, Hayashi, Kenji, Asakura, Hirofumi, Harada, Hideyuki, Hayashi, Nakamasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648164/
http://dx.doi.org/10.1093/noajnl/vdab159.099
_version_ 1784610746875772928
author Mitsuya, Koichi
Deguchi, Shoichi
Muto, Manabu
Yasui, Kazuaki
Onoe, Tsuyoshi
Ogawa, Hirofumi
Hayashi, Kenji
Asakura, Hirofumi
Harada, Hideyuki
Hayashi, Nakamasa
author_facet Mitsuya, Koichi
Deguchi, Shoichi
Muto, Manabu
Yasui, Kazuaki
Onoe, Tsuyoshi
Ogawa, Hirofumi
Hayashi, Kenji
Asakura, Hirofumi
Harada, Hideyuki
Hayashi, Nakamasa
author_sort Mitsuya, Koichi
collection PubMed
description BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation necrosis (RN). We treated with neoadjuvant fractionated stereotactic radiotherapy (Na-fSRT) followed by surgery for large brain metastasis with piecemeal resection. METHODS: Twelve patients received Na-fSRT followed by surgery between July 2019 and April 2021. Na-fSRT dose was based on lesion size and was standard dosing. Surgery generally followed within 7 days after radiotherapy. RESULTS: The mean age was 68 years (51–79). Sixteen men and five women. Mean follow-up period was 8.5 months (1–24.9). Primary were lung; 10 (NSCLC; 9, SCLC (recurrence); 1), esophagus; 3, colon; 2, melanoma; 2, kidney; 2 (recurrence1), uterus body; 1, and liver; 1. The median maximum tumor diameter was 3.6 cm (2.6–4.9). Median PTV, GTV volume were 21.7ml, 15.5ml, respectively. The median fSRT dose was 30Gy/5fr, and the median time from fSRT to surgery was 4 days (1–7). As preoperative adverse event, intracranial hypertension and partial seizure grade 2 (CTCAE ver.5) were occurred, but controlled with steroid and osmotic diuretics and anticonvulsant. Grade 3 and more adverse events were not occurred. Gross total removal was performed in 95.2%. Event cumulative incidence as follows: cavity local recurrence 4.8% (subtotal removal case); distant brain failure 33%; LMD 4.8%; and symptomatic RN 0%. The median intracranial progression free survival was 7 months, and median overall survival was 8.4 months. CONCLUSIONS: Na-fSRT followed by piecemeal resection is safety and feasible, and may have therapeutic value for deep large brain metastasis and eloquent lesion. Further prospective investigations in multi-institutional settings are warranted.
format Online
Article
Text
id pubmed-8648164
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86481642021-12-07 MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor Mitsuya, Koichi Deguchi, Shoichi Muto, Manabu Yasui, Kazuaki Onoe, Tsuyoshi Ogawa, Hirofumi Hayashi, Kenji Asakura, Hirofumi Harada, Hideyuki Hayashi, Nakamasa Neurooncol Adv Supplement Abstracts BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation necrosis (RN). We treated with neoadjuvant fractionated stereotactic radiotherapy (Na-fSRT) followed by surgery for large brain metastasis with piecemeal resection. METHODS: Twelve patients received Na-fSRT followed by surgery between July 2019 and April 2021. Na-fSRT dose was based on lesion size and was standard dosing. Surgery generally followed within 7 days after radiotherapy. RESULTS: The mean age was 68 years (51–79). Sixteen men and five women. Mean follow-up period was 8.5 months (1–24.9). Primary were lung; 10 (NSCLC; 9, SCLC (recurrence); 1), esophagus; 3, colon; 2, melanoma; 2, kidney; 2 (recurrence1), uterus body; 1, and liver; 1. The median maximum tumor diameter was 3.6 cm (2.6–4.9). Median PTV, GTV volume were 21.7ml, 15.5ml, respectively. The median fSRT dose was 30Gy/5fr, and the median time from fSRT to surgery was 4 days (1–7). As preoperative adverse event, intracranial hypertension and partial seizure grade 2 (CTCAE ver.5) were occurred, but controlled with steroid and osmotic diuretics and anticonvulsant. Grade 3 and more adverse events were not occurred. Gross total removal was performed in 95.2%. Event cumulative incidence as follows: cavity local recurrence 4.8% (subtotal removal case); distant brain failure 33%; LMD 4.8%; and symptomatic RN 0%. The median intracranial progression free survival was 7 months, and median overall survival was 8.4 months. CONCLUSIONS: Na-fSRT followed by piecemeal resection is safety and feasible, and may have therapeutic value for deep large brain metastasis and eloquent lesion. Further prospective investigations in multi-institutional settings are warranted. Oxford University Press 2021-12-06 /pmc/articles/PMC8648164/ http://dx.doi.org/10.1093/noajnl/vdab159.099 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Mitsuya, Koichi
Deguchi, Shoichi
Muto, Manabu
Yasui, Kazuaki
Onoe, Tsuyoshi
Ogawa, Hirofumi
Hayashi, Kenji
Asakura, Hirofumi
Harada, Hideyuki
Hayashi, Nakamasa
MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title_full MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title_fullStr MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title_full_unstemmed MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title_short MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
title_sort met-6 neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648164/
http://dx.doi.org/10.1093/noajnl/vdab159.099
work_keys_str_mv AT mitsuyakoichi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT deguchishoichi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT mutomanabu met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT yasuikazuaki met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT onoetsuyoshi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT ogawahirofumi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT hayashikenji met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT asakurahirofumi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT haradahideyuki met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor
AT hayashinakamasa met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor